Stock NAM NAMWIWAT MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Namwiwat Medical Corporation

Equities

NAM

THB663010007

End-of-day quote Thailand S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
4.8 THB -0.83% Intraday chart for Namwiwat Medical Corporation +3.45% -30.94%
May. 29 Namwiwat Medical Corporation Public Company Limited Announces Establishment of Joint Venture Company with Vimut Hospital Holding Company Limited CI
May. 14 Namwiwat Medical Corporation Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
NAMWIWAT MEDICAL CORPORATION Stock Namwiwat Medical Corporation
-30.94% 91.24M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-7.16% 178B
C+
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.04B
A
DEXCOM, INC. Stock DexCom, Inc.
-4.28% 47.24B
B-
CENCORA, INC. Stock Cencora, Inc.
+10.32% 44.62B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.14% 42.5B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.76% 29.99B
B
TERUMO CORPORATION Stock Terumo Corporation
+15.53% 25.22B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.88% 24.14B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-5.38% 23.69B
B
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. NAM Stock
  4. Ratings Namwiwat Medical Corporation